上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

601607 上海医药

交易中 07-17 13:27:02

{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":19.56,"timestamp":1721194022000,"preClose":19.28,"halted":0,"volume":9187643,"delay":0,"floatShares":1932000000,"shares":3704000000,"eps":1.0241,"marketStatus":"交易中","marketStatusCode":2,"change":0.28,"latestTime":"07-17 13:27:02","open":19.2,"high":19.63,"low":19.09,"amount":178000000,"amplitude":0.028,"askPrice":19.57,"askSize":116,"bidPrice":19.56,"bidSize":173,"shortable":0,"etf":0,"ttmEps":1.0241,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721199600000},"adr":0,"adjPreClose":19.28,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":21.21,"lowLimit":17.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3703626953,"pbRate":1.02,"roa":"--","roe":"2.23%","epsLYR":1.02,"committee":-0.497034,"marketValue":72443000000,"floatMarketCap":37787000000,"peRate":19.099698,"changeRate":0.0145,"turnoverRate":0.0048,"status":0},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2451961327","title":"上海医药(02607)下属控股子公司上药中西的盐酸缬更昔洛韦片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2451961327","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451961327?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:03","pubTimestamp":1721124218,"startTime":"0","endTime":"0","summary":"上海医药(02607)发布公告，近日，该公司下属控股子公司上海上药中西制药有限公司...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_46.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0097","BK0012","BK0188","BK0028","BK0196","02607","601607","BK0175","BK1197","BK0099","BK0187","BK0183","BK0209","BK0020","BK0184"],"gpt_icon":0},{"id":"2451965406","title":"上海医药(601607.SH)：盐酸缬更昔洛韦片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2451965406","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451965406?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:25","pubTimestamp":1721121940,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属控股子公司上海上药中西制药有限公司(以下简称“上药中西”)的盐酸缬更昔洛韦片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2024S01515)。盐酸缬更昔洛韦片主要用于治疗成人获得性免疫缺陷综合症(AIDS)患者的巨细胞病毒(CMV)视网膜炎，预防存在CMV感染风险的实体器官移植患者的CMV感染。截至公告日，公司针对该药品已投入研发费用约人民币961.36万元。截至公告日，中国境内除上药中西外，目前暂无该药品生产厂家。IQVIA数据库显示，2023年该药品医院市场规模为人民币1,222万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0188","02607","BK0209","BK0187","BK1197","BK0183","BK0184","BK0028","BK0012","BK0196","BK0099","BK0020","BK0175","601607"],"gpt_icon":0},{"id":"2451152486","title":"上海医药(02607)将于7月22日派发A股每股现金红利0.41元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451152486","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451152486?lang=zh_cn&edition=full","pubTime":"2024-07-15 16:53","pubTimestamp":1721033605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，该公司将于2024年7月22日派发A股每股现金红利0.41元(含税)。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0020","BK0196","BK0099","BK0187","BK0188","601607","BK0209","BK0028","BK0184","02607","399300","BK0183","BK0175","BK1197","BK0097","BK0012","159982"],"gpt_icon":0},{"id":"2451861859","title":"上海医药(601607.SH)2023年年度权益分派：每股派0.41元 7月19日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2451861859","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451861859?lang=zh_cn&edition=full","pubTime":"2024-07-15 16:10","pubTimestamp":1721031058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布2023年年度权益分派实施公告，本次利润分配以方案实施前的公司总股本为基数，每股派发现金红利0.41元(含税)，股权登记日为2024/7/19，除权(息)日为2024/7/22。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0196","BK0097","BK0012","BK0175","BK0187","BK1197","BK0183","BK0099","BK0209","601607","02607","BK0184","BK0020"],"gpt_icon":0},{"id":"2450854384","title":"上海医药07月10日遭主力抛售1315万元 环比增加102.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450854384","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450854384?lang=zh_cn&edition=full","pubTime":"2024-07-10 15:18","pubTimestamp":1720595922,"startTime":"0","endTime":"0","summary":"07月10日, 上海医药股价跌1.77%，报收18.83元，成交金额1.56亿元，换手率0.43%，振幅2.19%，量比0.81。上海医药今日主力资金净流出1315万元，连续3日净流出，上一交易日主力净流出650万元，今日环比增加102.31%。该股近5个交易日下跌0.48%，主力资金累计净流出3397万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1.76亿元，其中净流出天数为14日。净流出前三个股分别为益丰药房、大参林、上海医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710153002959cd8e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710153002959cd8e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0209","BK0188","BK0097","BK0187","BK0012","BK0099","BK0184","601607","BK0175","BK0020","BK0196","BK0183"],"gpt_icon":0},{"id":"2449470136","title":"上海医药最新公告：枸橼酸托法替布原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449470136","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449470136?lang=zh_cn&edition=full","pubTime":"2024-07-08 22:29","pubTimestamp":1720448980,"startTime":"0","endTime":"0","summary":"上海医药公告，近日公司下属全资子公司上药中西的枸橼酸托法替布原料药收到国家药品监督管理局颁发的化学原料药上市申请批准通知书，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800032579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0028","BK0209","BK0188","BK0097","BK0187","02607","BK0012","BK0099","BK0184","601607","BK0175","BK0020","BK0196","BK0183"],"gpt_icon":0},{"id":"2449763729","title":"上海医药(02607.HK)旗下治疗关节炎原料药获内地批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2449763729","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449763729?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:04","pubTimestamp":1720429440,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) (601607.SH) 公布，其全资子公司上药中西的枸橼酸托法替布原料药近日收到国家药监局颁发的《化学原料药上市申请批准通知书》，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞(PFE.US)  研发，制剂最早于2012年美国上市。截至目前，公司针对该药物已投入研发费用约1,269万元人民币。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-08 16:25。) (A股报价延迟最少十五分钟。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1362049/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK0187","BK0196","BK0012","BK0020","601607","BK0097","BK0028","BK1197","BK0209","02607","BK0188","BK0099","BK0175","BK0184"],"gpt_icon":0},{"id":"2449729302","title":"上海医药(02607)：枸橼酸托法替布原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449729302","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449729302?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:57","pubTimestamp":1720429055,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，公司下属全资子公司上海中西三维药业有限公司(上药中西)的枸橼酸托法替布原料药收到国家药品监督管理局颁发的《化学原料药上市申请批准通知书》(通知书编号：2024YS00606)，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞公司研发，制剂最早于2012年美国上市。2022年9月，上药中西就该药物向国家药监局递交上市申请并获受理;近日，上药中西收到国家药监局下发的《化学原料药上市申请批准通知书》。截至本公告日，公司针对该药物已投入研发费用约人民币1269万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0097","BK0183","BK0184","BK0187","601607","BK0099","BK0175","BK0028","BK0209","BK1197","BK0012","BK0188","02607","BK0020"],"gpt_icon":0},{"id":"2449728812","title":"上海医药(601607.SH)：枸橼酸托法替布原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2449728812","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449728812?lang=zh_cn&edition=full","pubTime":"2024-07-08 15:51","pubTimestamp":1720425118,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，公司下属全资子公司上海中西三维药业有限公司(简称“上药中西”)的枸橼酸托法替布原料药收到国家药品监督管理局颁发的《化学原料药上市申请批准通知书》(通知书编号：2024YS00606)，该药品获得批准生产。枸橼酸托法替布主要适用于治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎，由辉瑞公司研发，制剂最早于2012年美国上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","BK0020","02607","BK0012","BK0175","BK0187","601607","BK0184","BK0209","BK0099","BK0097","BK0196","BK0183","BK0188","BK0028"],"gpt_icon":0},{"id":"2448412491","title":"上海医药(02607)：股票期权限制行权期为7月8日至7月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2448412491","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448412491?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:53","pubTimestamp":1720083228,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，关于2019年A股股票期权激励计划首次授予股票期权第三个行权期及预留股票期权第二个行权期限制行权期间：一、首次授予股票期权第三个行权期自2024年2月14日起至2025年2月13日止;预留股票期权第二个行权期自2024年2月8日起至2025年2月7日止。二、本次限制行权期为2024年7月8日至2024年7月22日，在此期间全部激励对象将限制行权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0020","BK0196","BK0099","601607","BK0209","BK0175","BK0184","BK0183","BK0187","BK0188","BK0028","BK1197","BK0012","BK0097"],"gpt_icon":0},{"id":"2448546416","title":"上海医药07月04日遭主力抛售2420万元 环比增加162.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448546416","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448546416?lang=zh_cn&edition=full","pubTime":"2024-07-04 15:19","pubTimestamp":1720077575,"startTime":"0","endTime":"0","summary":"07月04日, 上海医药股价跌1.11%，报收18.71元，成交金额1.80亿元，换手率0.50%，振幅1.80%，量比0.87。上海医药今日主力资金净流出2420万元，连续4日净流出，上一交易日主力净流出922万元，今日环比增加162.47%。该股近5个交易日下跌2.81%，主力资金累计净流出6084万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2.14亿元，其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041539179573a341&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041539179573a341&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601607","BK0175","BK0012","BK0097","BK0184","BK0209","BK0099","BK0187","BK0028","BK0188","BK0196","BK0183","BK0020"],"gpt_icon":0},{"id":"2448723871","title":"上海医药(02607)：依折麦布片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448723871","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448723871?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:40","pubTimestamp":1719999611,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，公司控股子公司常州制药厂有限公司(常州制药厂)的依折麦布片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2024S01240)，该药品获得批准生产。依折麦布片主要用于原发性高胆固醇血症、纯合子家族性高胆固醇血症(HoFH)和纯合子谷甾醇血症(或植物甾醇血症)等症状。最早ORGANON研发，并于2002年在美国上市。2022年12月，常州制药厂就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币1447.67万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0209","BK0099","02607","BK0020","BK0175","BK0183","BK0097","BK0188","BK1197","BK0028","BK0187","BK0012","601607","BK0196"],"gpt_icon":0},{"id":"2448172634","title":"上海医药(02607.HK)依折麦布片获准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448172634","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448172634?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:40","pubTimestamp":1719999600,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布，控股子公司常州制药厂的药品“依折麦布片”近日收到国家药监局颁发药品注册证书，获批准生产。依折麦布片主要用于原发性高胆固醇血症、纯合子家族性高胆固醇血症（HoFH）和纯合子谷甾醇血症（或植物甾醇血症）等症状。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-03 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361153/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0196","BK0028","BK0012","BK0020","BK0188","BK0209","601607","BK0097","02607","BK1197","BK0187","BK0099","BK0184","BK0175","BK0183"],"gpt_icon":0},{"id":"2448844133","title":"上海医药(02607)：磷酸西格列汀片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448844133","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448844133?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:29","pubTimestamp":1719912573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，该公司控股子公司常州制药厂有限公司的磷酸西格列汀片收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。磷酸西格列汀片主要用于改善2型糖尿病患者的血糖控制。因此常州制药厂有限公司的磷酸西格列汀片获得批准生产，有利于扩大该药品的市场份额，提升市场竞争力，同时为公司后续产品开展仿制药申报积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0183","02607","BK0188","BK0175","BK1197","BK0012","BK0097","BK0099","BK0187","BK0184","BK0196","BK0028","BK0020","601607"],"gpt_icon":0},{"id":"2448348138","title":"上海医药最新公告：磷酸西格列汀片获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448348138","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448348138?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:10","pubTimestamp":1719911426,"startTime":"0","endTime":"0","summary":"上海医药公告，控股子公司常州制药厂的磷酸西格列汀片获得国家药监局批准生产。该药品主要用于改善2型糖尿病患者的血糖控制。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200026895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0012","BK0188","BK0183","BK0184","BK0099","BK0020","BK0097","02607","BK0028","BK0175","BK0196","BK0209","BK0187","601607"],"gpt_icon":0},{"id":"2448806211","title":"上海医药(601607.SH)：磷酸西格列汀片获批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448806211","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448806211?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:03","pubTimestamp":1719911015,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，公司控股子公司常州制药厂有限公司(简称“常州制药厂”)的磷酸西格列汀片收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。磷酸西格列汀片主要用于改善2型糖尿病患者的血糖控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0028","601607","BK0099","BK0184","BK0187","BK0020","BK0196","BK0183","BK0012","BK0188","BK1197","BK0097","02607","BK0175"],"gpt_icon":0},{"id":"2448663139","title":"上海医药最新公告：WST03制剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2448663139","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448663139?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:39","pubTimestamp":1719823192,"startTime":"0","endTime":"0","summary":"上海医药公告，公司全资子公司上药信谊收到国家药监局关于WST03制剂的临床试验批准通知书，将于近期启动国内I期临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100021538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0020","BK0097","BK0209","BK1583","BK1141","BK0184","BK1197","BK0183","BK0188","601607","03347","BK0196","BK0028","BK0187","BK0099","BK0175","02607","BK1576"],"gpt_icon":0},{"id":"2448965452","title":"上海医药(601607.SH)：WST03制剂临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2448965452","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448965452?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:36","pubTimestamp":1719822969,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，公司全资子公司上海上药信谊药厂有限公司(简称“上药信谊”)收到国家药品监督管理局下发的关于WST03制剂(胶囊)的《药物临床试验批准通知书》，将于近期启动国内I期临床试验。WST03是阴道用微生态活菌制剂，拟用于治疗细菌性阴道病(BV)。临床前研究显示WST03制剂具有有效治疗BV并预防其复发的作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0012","601607","BK0028","BK1197","02607","BK0187","BK0184","BK0196","BK0097","BK0188","BK1583","BK1141","BK1576","BK0175","BK0020","03347","BK0209","BK0099"],"gpt_icon":0},{"id":"2446685898","title":"上海医药公布2023财年年度权益分配方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2446685898","media":"同花顺金融研究...","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446685898?lang=zh_cn&edition=full","pubTime":"2024-06-28 22:01","pubTimestamp":1719583316,"startTime":"0","endTime":"0","summary":"同花顺财经讯 上海医药（02607.HK）6月28日发布公告，公司将于2024年8月27日一般分红每股0.440674港元，除净日为7月18日。 上海医药的2023财年年报显示，截至2023年12月31日实现营业收入260 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240628/c659333991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0175","BK0187","BK0012","601607","BK0020","BK0188","BK0099","BK0184","BK0209","BK0196","BK0183","BK0028","BK0097"],"gpt_icon":0},{"id":"2446503569","title":"上海医药(02607)：张文学获正式选举为第八届董事会非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2446503569","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446503569?lang=zh_cn&edition=full","pubTime":"2024-06-28 19:19","pubTimestamp":1719573599,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，于股东周年大会上，张文学获股东正式选举为第八届董事会非执行董事，任期至第八届董事会届满时止，自2024年6月28日起生效。于2024年6月28日举行的公司董事会上，非执行董事张文学由董事会推选为董事会战略委员会委员，执行董事杨秋华和独立非执行董事王忠分别作为董事会战略委员会召集人和委员的身份不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0187","BK0012","BK0184","BK0099","BK0028","BK0183","BK1197","BK0196","BK0175","BK0188","BK0097","BK0020","601607","02607"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":0.0433},{"period":"3month","weight":0.0973},{"period":"6month","weight":0.2126},{"period":"1year","weight":-0.0604},{"period":"ytd","weight":0.1524}],"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","perCapita":"23812股","boardName":"零售业","registeredCapital":"370362万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":"　　上海医药集团股份有限公司主营业务为医药研发与制造、分销与零售。主要产品为丹参酮ⅡA磺酸钠注射液、注射用乌司他丁、硫酸羟氯喹片、注射用二丁酰环磷腺苷钙、注射用盐酸头孢替安、丹参片、参麦注射液、瓜蒌皮注射液、尪痹片、银杏酮酯等。集团在证券之星、第一财经以及上海市股份公司联合会共举办的\"上海上市公司评选\"中荣获\"最佳转型奖\"。中国医药上市公司竞争力50强榜首,中国医药行业\"十大最具影响力企业\"之一,\"投资者关系管理百强\";荣列上海企业100强第19位、上海制造业企业50强第9位、中国企业500强第203位、中国制造业企业500强第99位、中国制药工业百强第3位等。","serverTime":1721194025664,"listedPrice":4.5,"stockholders":"81129人(较上一季度增加Infinity%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}